CAR-T cell therapy for DLL3-positive small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new CAR-T cell therapy (GC511B) for people with a specific type of small cell lung cancer that has DLL3 protein. The treatment uses your own immune cells to target and attack the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have small cell lung cancer that has come back or is not responding to standard treatment, and your tumor cells test positive for a protein called DLL3.
- You are healthy enough to carry out daily activities with little or no help (ECOG score 0-2).
- You have not had a previous CAR-T cell therapy or any other gene-edited cell therapy.
- You have not had major surgery or certain treatments (like chemotherapy, immunotherapy, or radiation) in the last few weeks before the study starts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental therapy (NEUK203-13) for people with neuroendocrine tumors, including small cell lung cancer, that have not responded to or stopped responding to standard treatments. It aims to see if the drug is safe and to look for early signs that it might shrink tumors, especially in people whose tumors have a specific marker called DLL3.
This trial tests a new type of immune cell therapy (NKG2D CAR-T cells) for people with advanced solid tumors that have not responded to standard treatments. It aims to see if these specially engineered cells can shrink tumors or slow their growth.
This trial tests a new cell therapy called TC-D101 for people with a type of small cell lung cancer that has DLL3 protein on its surface. It may be an option if standard treatments have stopped working or are not suitable.
This trial tests a new CAR-T cell therapy that targets two proteins (PD-L1 and DLL3) on small cell lung cancer cells. It's for people whose cancer came back or got worse after standard chemotherapy, and it aims to see if the treatment is safe and works.
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
This study tests DJI136, a new type of cell therapy that trains your immune cells to fight small cell lung cancer. The therapy targets a protein called DLL3 found on cancer cells. It's designed for patients whose cancer has returned or progressed after initial chemotherapy and immunotherapy.
Hear when a new Relapsed/Refractory Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.